Guideline‑Directed Medical Therapy for HFrEF (European Society of Cardiology)

Foundational Pharmacologic Therapy

SGLT2 inhibitors (dapagliflozin 10 mg daily or empagliflozin 10 mg daily) are recommended for all patients with HFrEF (LVEF ≤ 40%) regardless of diabetes status (Class I, strong evidence). 1
SGLT2 inhibitors have minimal blood‑pressure‑lowering effects, making them suitable as first‑line agents even in patients with low baseline BP. (Class I, moderate evidence) 2
Sacubitril/valsartan is the preferred RAAS inhibitor, providing an additional ≈20 % relative mortality reduction compared with enalapril (Class I, strong evidence). 1
In ambulatory HFrEF patients who remain symptomatic despite optimal ACE‑I, β‑blocker, and MRA therapy, sacubitril/valsartan should replace the ACE‑I. (Class I, strong evidence) 1
If an ARNI cannot be used, ACE‑I (e.g., enalapril) is recommended in addition to a β‑blocker to reduce HF hospitalisation and death (Class I, strong evidence). 1
Evidence‑based β‑blockers (carvedilol, metoprolol succinate, bisoprolol) each reduce mortality by ≥20 % and lower sudden cardiac death in HFrEF (Class I, strong evidence). 1
Selective β₁‑blockers may be preferred in patients with low BP because they cause less BP reduction than non‑selective agents (Class I, moderate evidence). 2
Mineralocorticoid receptor antagonists (spironolactone or eplerenone) added to ACE‑I/ARNI and β‑blocker confer ≥20 % mortality reduction and lower sudden death risk (Class I, strong evidence). 1
MRAs have minimal impact on blood pressure, allowing early initiation even in hypotensive patients (Class I, moderate evidence). 2

Implementation Strategy – Forced‑Titration Protocol

Start each GDMT drug at a low dose and increase at predefined intervals (typically every 1–2 weeks). (Class I, moderate evidence) 2
Asymptomatic vital‑sign or laboratory changes should not delay uptitration; only symptomatic hypotension, orthostatic symptoms, or clinically significant hyper‑kalaemia/renal dysfunction warrant dose adjustment. (Class I, moderate evidence) 2
Uptitrate one medication at a time using small increments until the highest tolerated or target dose is reached. (Class I, moderate evidence) 2

Sequencing for Patients with Low Blood Pressure

First step: initiate an SGLT2 inhibitor and an MRA (both have negligible BP‑lowering effect).** (Class I, moderate evidence) 2
Second step: add a low‑dose β‑blocker if resting heart rate > 70 bpm, or add low‑dose sacubitril/valsartan (25–50 mg twice daily).** (Class I, moderate evidence) 2
Third step: uptitrate each agent weekly with small increments.** (Class I, moderate evidence) 2
If β‑blockers are not hemodynamically tolerated and the patient is in sinus rhythm, ivabradine may be used to facilitate β‑blocker titration. (Class IIa, moderate evidence) 2

Adjunctive Pharmacologic Therapies

Loop diuretics are recommended to improve symptoms and exercise capacity in patients with congestion (Class I, strong evidence). 1
Loop diuretics should be titrated to achieve euvolemia; they do not confer mortality benefit. (Class I, moderate evidence) 2
Over‑diuresis can lower blood pressure and should be avoided. (Class I, moderate evidence) 2

Medications to Avoid (Class III: Harm)

Diltiazem and verapamil are contraindicated in HFrEF because they increase the risk of HF worsening and hospitalisation. (Class III, strong evidence) 1
Adding an ARB (or renin inhibitor) to a regimen that already includes ACE‑I and an MRA is not recommended due to heightened risk of renal dysfunction and hyper‑kalaemia. (Class III, strong evidence) 1

Device Therapy

Primary‑prevention ICD: indicated for symptomatic HFrEF (NYHA II–III) with LVEF ≤ 35 % after ≥3 months of optimal GDMT and an expected survival > 1 year with good functional status.** (Class I, strong evidence) 1
Secondary‑prevention ICD: indicated for patients who have survived a ventricular arrhythmia causing hemodynamic instability, with expected survival > 1 year.** (Class I, strong evidence) 1
ICD implantation is not recommended within 40 days of myocardial infarction, as it does not improve prognosis in that early period. (Class I, strong evidence) 1

Implementation Gaps and Solutions

Real‑world data show that only 46–47 % of patients receive all four foundational drug classes simultaneously, and < 50 % achieve ≥50 % of target doses for RAAS inhibitors/ARNI and β‑blockers. (Observational evidence) 3
Use of forced‑titration protocols with predefined 1–2‑week uptitration schedules improves the proportion of patients reaching target doses. (Class I, moderate evidence) 2
Asymptomatic low blood pressure should not prevent initiation or uptitration of GDMT; start with SGLT2 inhibitors and MRAs first. (Class I, moderate evidence) 2

All facts are derived from European Society of Cardiology guideline recommendations and associated evidence levels as cited.

Guideline‑Directed Medical Therapy for Heart Failure with Reduced Ejection Fraction (HFrEF)

Core Pharmacologic Pillars (Class I, AHA/ACC/HFSA)

All patients with HFrEF should receive the four foundational medication classes—SGLT2 inhibitor, ARNI (or ACE‑I/ARB), evidence‑based β‑blocker, and mineralocorticoid‑receptor antagonist—initiated rapidly and titrated to target doses using a forced‑titration strategy. 4
The 2022 AHA/ACC/HFSA guidelines designate SGLT2 inhibitors as the fourth pillar of GDMT for HFrEF, joining the three traditional neuro‑hormonal antagonist classes. 4
Each of the four pillars reduces all‑cause mortality by ≥20 % and lowers the risk of sudden cardiac death in HFrEF patients. [5][6]7

SGLT2‑Inhibitor Therapy (Class I)

Dapagliflozin 10 mg daily (target 10 mg) and empagliflozin 10 mg daily (target 10–25 mg) lower HF hospitalizations and cardiovascular death irrespective of diabetes status. 4
SGLT2 inhibitors may be started immediately without waiting for other GDMT agents to reach target doses. 8

ARNI (Sacubitril/Valsartan) (Class I)

Sacubitril/valsartan (starting 24/26 mg or 49/51 mg BID, target 97/103 mg BID) is preferred over ACE‑I/ARB because it yields an ≈20 % relative mortality reduction. [5][6]
It also promotes reverse cardiac remodeling independent of background therapy. 8

*If ARNI cannot be used, ACE‑I (e.g., enalapril 2.5 mg BID → 10–20 mg BID) or ARB (e.g., lisinopril 2.5–5 mg daily → 20–40 mg daily) provide a modest mortality benefit (5–16 % risk reduction) but do not reduce sudden death. [5][6]

Evidence‑Based β‑Blockers (Class I)

Carvedilol, metoprolol succinate, and bisoprolol are the only β‑blockers proven to prolong life in HFrEF, each reducing mortality by ≥20 % and decreasing sudden cardiac death. [5][6]

Mineralocorticoid‑Receptor Antagonists (Class I)

Spironolactone (12.5–25 mg → 25–50 mg daily) and eplerenone (25 mg → 50 mg daily) each confer ≥20 % mortality reduction and lower sudden death risk. [5][6]

Forced‑Titration Implementation Strategy (Class I)

Landmark mortality‑benefit trials employed forced‑titration; maintaining patients on sub‑target doses has not been shown to prolong life. [5][7]
Protocol: start each drug at a low dose, increase at predefined intervals, aim for the same target dose for all patients unless a clinically meaningful adverse event occurs; asymptomatic vital‑sign or laboratory changes should not delay uptitration. 5
Temporary dose reductions or discontinuations are allowed, but clinicians should promptly reinstitute therapy and achieve target doses; sub‑target dosing is acceptable only when higher doses threaten clinical stability. 5

Sequencing & Timing (Class I)

All four GDMT classes can be initiated simultaneously at low doses, or sequentially without waiting for any single agent to reach its target dose before adding the next. 8

Special Populations

African‑American Patients (Class I)

Add hydralazine‑isosorbide dinitrate (start 25 mg/20 mg TID → target 75 mg/40 mg TID) when symptomatic despite optimal GDMT; a fixed‑dose combination (20/37.5 mg TID → 2 tablets TID) is available. This combination reduces mortality when added to ACE‑I, β‑blocker, and MRA. 9

Patients Requiring Diuretics (Class I)

Loop diuretics are used for fluid retention and symptom relief; titrate to achieve euvolemia. Diuretics do not confer mortality benefit. [10][11]4

Additional Pharmacologic Options

Ivabradine (Class IIa): for patients in sinus rhythm with resting HR ≥ 70 bpm despite β‑blocker optimization; start 2.5–5 mg BID, titrate to HR 50–60 bpm (max 7.5 mg BID). 8
Digoxin (Class IIb): may reduce HF hospitalizations but does not improve mortality. 7

Device Therapy (Class I)

Implantable cardioverter‑defibrillator (ICD): indicated for primary prevention in patients with LVEF ≤ 35 % after ≥3 months of optimal GDMT. 9
Cardiac resynchronization therapy (CRT): indicated for LVEF ≤ 35 %, sinus rhythm, left‑bundle‑branch block, and QRS duration ≥ 150 ms after GDMT. 9
Devices should be considered only after an adequate trial of GDMT; medication optimization precedes device implantation. 6

Follow‑Up & LVEF Recovery

Patients whose LVEF improves to > 40 % should continue all HFrEF therapies indefinitely, as discontinuation raises the risk of recurrent LV dysfunction and adverse outcomes. 4

Scope of Recommendations

The guidance applies specifically to HFrEF (LVEF ≤ 40 %). For HFmrEF (LVEF 41‑49 %) and HFpEF (LVEF ≥ 50 %), evidence for GDMT is weaker (Class IIa–IIb) and only SGLT2 inhibitors have strong supporting data in HFpEF. [4][12]

Foundational Quadruple Guideline Therapy for HFrEF

1. SGLT2‑Inhibitor Therapy (First‑Line)

2. ARNI (Sacubitril/Valsartan) – Preferred RAAS Inhibitor

3. Evidence‑Based β‑Blockers

4. Mineralocorticoid Receptor Antagonists (MRAs)

5. Device Therapy

6. Medications to Avoid (Class III Harm)

Continuation of Guideline‑Directed Medical Therapy After Ejection‑Fraction Recovery

1. Evidence Supporting Ongoing Use of GD M T (Dapagliflozin + Sacubitril/Valsartan)

The European Society of Cardiology (ESC) Heart Failure Association states that guideline‑directed medical therapy—including dapagliflozin and sacubitril/valsartan—continues to provide mortality and morbidity reduction even after left‑ventricular ejection fraction normalizes. 17
The ESC HFA further clarifies that asymptomatic changes in vital signs (e.g., modest blood‑pressure rise from improved cardiac output) should not prompt dose reduction; dose adjustments are reserved for symptomatic hypotension, orthostatic symptoms, clinically significant hyperkalaemia, or renal dysfunction. 18

2. Sacubitril/Valsartan Dosing Recommendations

The Canadian Cardiovascular Society (CCS) specifies the target maintenance dose as 97 mg/103 mg twice daily, with dose escalation every 2–4 weeks as tolerated. 19
If a temporary dose reduction is required because of adverse effects, the previously tolerated dose should be reinstated as soon as it is safe. 19
The CCS notes that sub‑target dosing has not demonstrated a survival benefit, reinforcing the importance of maintaining the target dose whenever possible. 20

3. Dapagliflozin Dosing and Renal Considerations

The ADA/KDIGO consensus (cited in Kidney International) recommends dapagliflozin 10 mg daily be continued for renal and cardiovascular protection until the patient requires dialysis, even when estimated glomerular filtration rate falls below 25 mL/min/1.73 m². 21
The same consensus indicates no dose reduction is indicated when ejection fraction improves; the standard 10 mg daily dose remains appropriate regardless of cardiac response. 21

4. Monitoring, Follow‑Up, and Re‑Assessment of EF

The CCS advises re‑assessment of left‑ventricular ejection fraction every 1–5 years or sooner if clinical status changes, with repeat echocardiography at 6 months and 12 months after optimization of GD M T. 22
Routine clinical follow‑up should occur every 1–3 years (or sooner with any change in symptoms). 22

5. Management of Symptomatic Hypotension in Patients on GD M T

When symptomatic hypotension develops, the CCS recommends first reducing or discontinuing diuretics (which lack mortality benefit) before considering any dose reduction of sacubitril/valsartan. 19
If hypotension persists after diuretic adjustment, a temporary halving of the sacubitril/valsartan dose may be employed, with plans to re‑uptitrate once the patient is hemodynamically stable. 22

6. Uptitration Feasibility After EF Improvement

The ESC HFA notes that improved ejection fraction often enhances hemodynamic tolerance, making uptitration to target doses of sacubitril/valsartan more feasible rather than less. 17

All bullet points are derived from cited references and reflect guideline‑level recommendations where explicitly stated.